Evidence mapPaperPMID 35485648Full record

ArticleCancer science2022

The HOXC-AS2/miR-876-5p/HKDC1 axis regulates endometrial cancer progression in a high glucose-related tumor microenvironment.

Jing Guo, Feng Ye, Wenli Xie, Xinxin Zhang, Ru Zeng, Wang Sheng, Yanjun Mi, Xiugui Sheng

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Advances in MiRNAs Involved in Endometrial Carcinoma.Combinatorial chemistry & high throughput screening · 2025
    Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Jing GuoDepartment of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.
Feng YeDepartment of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.
Wenli XieDepartment of Gynecology, The Second Hospital of Shandong University, Jinan, Shandong, China.
Xinxin ZhangDepartment of Gynecologic Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong, China.
Ru ZengDepartment of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.
Wang ShengDepartment of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.
Yanjun MiDepartment of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.
Xiugui ShengCancer Hospital of Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, Guangdong, China.ORCID https://orcid.org/0000-0002-8003-0263
First Affiliated Hospital of Xiamen University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNSecond Hospital of Shandong University · CNShandong University · CN

Funding

Fujian Natural Science Foundation (Youth Innovation) Project 2020J05308National Major Scientific and Technological Special Project for "Significant New Drugs Development" 2020ZX09201005National Natural Science Foundation of China NSFC81672591Sanming Project of Medicine in Shenzhen SZSM201812075Shenzhen Healthcare Research Project SZLY2017030Special Fund for Scientific Talents of the First Affiliated Hospital of Xiamen University ZLYY201906Taishan Scholars ts201511073Xiamen Medical and Health Guiding Project Fund Project 3502Z20214ZD1020
6 · The paper itself

Abstract

The tumor microenvironment (TME) is related to chronic inflammation and is currently identified as a risk factor for the occurrence and development of endometrial cancer (EC). Pyroptosis is a new proinflammatory form of programmed cell death that plays a critical role in the progression of multiple diseases. However, the important role of pyroptosis in high-glucose (HG)-related EC and the underlying molecular mechanisms remain elusive. In the present study, transcriptome high-throughput sequencing revealed significantly higher hexokinase domain-containing 1 (HKDC1) expression in EC patients with diabetes than in EC patients with normal glucose. Mechanistically, HKDC1 regulates HG-induced cell pyroptosis by modulating the production of reactive oxygen species and pyroptosis-induced cytokine release in EC. In addition, HKDC1 regulates TME formation by enhancing glycolysis, promoting a metabolic advantage in lactate-rich environments to further accelerate EC progression. Subsequently, miR-876-5p was predicted to target the HKDC1 mRNA, and HOXC-AS2 was identified to potentially inhibit the miR-876-5p/HKDC1 axis in regulating cell pyroptosis in HG-related EC. Collectively, we elucidated the regulatory role of the HOXC-AS2/miR-876-5p/HKDC1 signal transduction axis in EC cell pyroptosis at the molecular level, which may provide an effective therapeutic target for patients with diabetes who are diagnosed with EC.

Indexed as

Endometrial NeoplasmsHexokinaseMicroRNAsRNA, Long NoncodingFemaleGlucoseHumansTumor MicroenvironmentGlucoseHexokinaseHKDC1 protein, humanMicroRNAsMIRN876 microRNA, humanRNA, Long Noncodingendometrial cancerhigh glucoseHKDC1pyroptosistumor microenvironment

Identifiers

PMID35485648
PMCPMC9277262
OpenAlexW4225117243

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.